New drug combo shows promise for rare, aggressive prostate cancer

NCT ID NCT04848337

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants will receive the drugs in 21-day cycles for up to 35 cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma neuroendocrine neoplasm prostate neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS PROSTATE CANCER METASTATIC

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Froedtert and The Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Oregon health

Portland, Oregon, 97239, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States
Winship Cancer Instituted of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.